Gelesis to Participate in Upcoming Investor Conferences
Gelesis (NYSE: GLS), the maker of Plenity for weight management,
today announced that Yishai Zohar, Founder and Chief Executive
Officer, Elliot Maltz, Chief Financial Officer, and David Pass,
Chief Operating and Commercial Officer, will participate in two
upcoming investor conferences:
This press release features multimedia. View
the full release here:
(Photo: Business Wire)
Wednesday, May 25, 2022: UBS Global Healthcare Conference:
Gelesis will host a presentation beginning at 8:30 a.m. Eastern
Time. The presentation will be webcast live here and on the
Company’s investor relations website at ir.gelesis.com.
Wednesday, June 1, 2022: Third Annual Loop Capital Conference:
Gelesis will participate virtually. Please contact your Loop
Capital representative for further details.
Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis”) is a
consumer-centered biotherapeutics company and the maker of
Plenity®, which is inspired by nature and FDA cleared to aid in
weight management. Our first-of-their-kind non-systemic
superabsorbent hydrogels are made entirely from naturally derived
building blocks. They are inspired by the composition and
mechanical properties of raw vegetables, taken by capsule, and act
locally in the digestive system, so people feel satisfied with
smaller portions. Our portfolio includes Plenity® and potential
therapies in development for patients with Type 2 Diabetes,
Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic
Steatohepatitis (NASH), and Functional Constipation. For more
information, visit gelesis.com, or connect with us on Twitter
Plenity® is indicated to aid weight management in adults with
excess weight or obesity, a Body Mass Index (BMI) of 25–40 kg/m²,
when used in conjunction with diet and exercise.
Important Safety Information about Plenity
- Patients who are pregnant or are allergic to cellulose, citric
acid, sodium stearyl fumarate, gelatin, or titanium dioxide should
not take Plenity.
- To avoid impact on the absorption of medications:
- For all medications that should be taken with food, take them
after starting a meal.
- For all medications that should be taken without food (on an
empty stomach), continue taking on an empty stomach or as
recommended by your physician.
- The overall incidence of side effects with Plenity was no
different than placebo. The most common side effects were diarrhea,
distended abdomen, infrequent bowel movements, and flatulence.
- Contact a doctor right away if problems occur. If you have a
severe allergic reaction, severe stomach pain, or severe diarrhea,
stop using Plenity until you can speak to your doctor.
Rx Only. For the safe and proper use of Plenity or more
information, talk to a healthcare professional, read the Patient
Instructions for Use, or call 1-844-PLENITY.
version on businesswire.com: https://www.businesswire.com/news/home/20220518006013/en/
Media & Investor
Relations Katie Sullivan email@example.com
Historical Stock Chart
From Jul 2022 to Aug 2022
Historical Stock Chart
From Aug 2021 to Aug 2022